ADCT news

The company is cutting its workforce globally by 17% to generate $10 million in annual savings. This reorganization enhances financial flexibility as the company advances ZYNLONTA regulatory filings.

ADC Therapeutics announced positive topline data from LOTIS-5 Phase 3 trial showing ZYNLONTA combined with rituximab achieved statistical significance on progression-free survival versus standard immunochemotherapy in relapsed/refractory DLBCL patients. The company plans to file a supplemental BLA w…

ADC Therapeutics SA updated its Articles of Association, establishing corporate governance structure with registered office in Epalinges, Switzerland. The filing documents standard organizational and operational provisions with no material changes to business operations or financial position.